Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial

Kenneth G. Saag*, Nicola Pannacciulli, Piet Geusens, Jonathan D. Adachi, Osvaldo D. Messina, Jorge Morales-Torres, Ronald Emkey, Peter W. Butler, Xiang Yin, Willem F. Lems

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1174-1184
Number of pages11
JournalArthritis & Rheumatology
Volume71
Issue number7
DOIs
Publication statusPublished - Jul 2019

Keywords

  • CORTICOSTEROID-INDUCED OSTEOPOROSIS
  • BONE-MINERAL DENSITY
  • POSTMENOPAUSAL WOMEN
  • ZOLEDRONIC ACID
  • VERTEBRAL FRACTURE
  • PREVENTION
  • ALENDRONATE
  • MULTICENTER
  • EXTENSION
  • THERAPY

Cite this

Saag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales-Torres, J., Emkey, R., Butler, P. W., Yin, X., & Lems, W. F. (2019). Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis & Rheumatology, 71(7), 1174-1184. https://doi.org/10.1002/art.40874